Breast Cancer

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Findings from the INSITE trial support the Medical Imaging Drugs Advisory Committee’s positive opinion on pegulicianine for breast cancer surgery.

Findings from a phase 2 trial support the premise that activating the androgen receptor may elicit antitumor effects in patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative breast cancer.

Carey K. Anders, MD, concludes with a look toward the future of HER2+ breast cancer treatment and provides advice to community oncologists treating patients with breast cancer.

An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.

An expert on metastatic breast cancer provides clinical insights gleaned from the HER2CLIMB-02 trial and discusses the design and rationale of the ongoing HER2CLIMB-05 study.

Following SABCS 2023, Carey K. Anders, MD, reviews recent updates from the KATHERINE and APHINITY clinical trials in HER2+ breast cancer.

The panelists conclude their discussion on HER2-positive breast cancer by underscoring the importance of preventive measures for brain metastases, enhanced strategies for managing leptomeningeal disease, and improved approaches to handle treatment-related toxicity.

Heather Moore, CPP, PharmD, shares expert insights on managing T-DXd-related adverse effects, including prophylactic measures for nausea and strategies for monitoring and management of ILD.

Rani Bansal, MD explores recent findings suggesting a risk of radiation necrosis in patients undergoing treatment with ADCs and concurrent radiotherapy for brain metastases and discusses the potential implications for future treatment approaches.

Rani Bansal, MD, discusses progressive developments in treating brain metastases in HER2-positive breast cancer, highlighting insights from the TUXEDO and DEBORAH trials, and examines the potential role of T-DXd in managing leptomeningeal disease.

Rani Bansal, MD, discusses the case of a 54-year-old post-menopausal patient who develops liver and brain metastases after undergoing prior therapy with trastuzumab/pertuzumab and T-DM1.

Heather Moore, CPP, PharmD examines the role of topical diclofenac gel in the management of hand and foot syndrome associated with capecitabine, highlighting key insights from the D-TORCH trial.

Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).

As the 41st Annual Miami Breast Cancer Conference approaches, Debu Tripathy, MD, prepares to step down as cochair.

A patient reported outcome analysis of the phase 3 OlympiA trial found that treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer ended.

The National Comprehensive Cancer Network has issued a category 2A recommendation for the use of goserelin for ovarian function suppression in those with breast cancer.

Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.

Carey Anders, MD, examines strategies for treating stable and active brain metastases in individuals with advanced HER2-positive breast cancer, highlighting key data from the HER2CLIMB trial.

Carey Anders, MD, discusses the scenario of a 34-year-old patient diagnosed with HER2-positive breast cancer, who develops brain metastases after undergoing initial therapy with dual HER2 blockade.

Heather Moore, CPP, PharmD, presents a comprehensive summary of targeted therapies for HER2-positive breast cancer and provides expert insights into the management of adverse effects associated with these treatments.

Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.

Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.

The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.

Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.